BET inhibitors: an updated patent review (2018–2021)

In recent years, an increasing number of structurally diverse BET inhibitors have been identified, including pan BET inhibitors, BD1 or BD2 selective BET inhibitors, bivalent BET inhibitors, kinase and BET dual inhibitors, and BET-PROTACs. Despite many challenges, BET inhibitors have high potential in the treatment of cancer and other diseases, and the development of next-generation BET inhibitors could be promising.